ArticleNucleic acids research2020
SPRINT: a Cas13a-based platform for detection of small molecules.
Article in Nucleic acids research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 86 citations in OpenAlex.
- Fluorogenic RNA Aptamer-Based Activity Quantification of T7 RNA Polymerase.Biochemistry · 2026Article
- Engineering Allosteric Transcription Factor-Based Biosensors: Advances and Prospects for Modern Food Contaminant Monitoring.Foods (Basel, Switzerland) · 2026Review
- Engineering stimuli-responsive CRISPR-Cas systems for versatile biosensing.Analytical and bioanalytical chemistry · 2025Review
- MAIGRET: a CRISPR-based immunoassay that employs antibody-induced cell-free transcription of CRISPR guide RNA strands.Nucleic acids research · 2025Article
- Fluorogenic RNA-Based Biosensors of Small Molecules: Current Developments, Uses, and Perspectives.Biosensors · 2024Review
- Unveiling the RNA-mediated allosteric activation discloses functional hotspots in CRISPR-Cas13a.Nucleic acids research · 2024Article
- Article
- Programmable RNA targeting with CRISPR-Cas13.RNA biology · 2024Review
- Recent advances and challenges of the use of the CRISPR/Cas system as a non-nucleic acid molecular diagnostic.Heliyon · 2023Review
- CRISPR Assays for Disease Diagnosis: Progress to and Barriers Remaining for Clinical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Cryo-EM structure and protease activity of the type III-E CRISPR-Cas effector.Nature microbiology · 2023Article
- Molecular Mechanisms Underlying CRISPR/Cas-Based Assays for Nucleic Acid Detection.Current issues in molecular biology · 2023Review
- Universal theranostic CRISPR/Cas13a RNA-editing system for glioma.Theranostics · 2023Article
- Bio-SCAN V2: A CRISPR/dCas9-based lateral flow assay for rapid detection of theophylline.Frontiers in bioengineering and biotechnology · 2023Article
- Recent Advances in CRISPR/Cas-Based Biosensors for Protein Detection.Bioengineering (Basel, Switzerland) · 2022Review
- Next-Generation Diagnostic with CRISPR/Cas: Beyond Nucleic Acid Detection.International journal of molecular sciences · 2022Review
- Development of Cas12a-Based Cell-Free Small-Molecule Biosensors via Allosteric Regulation of CRISPR Array Expression.Analytical chemistry · 2022Article
- Research progress of CRISPR-based biosensors and bioassays for molecular diagnosis.Frontiers in bioengineering and biotechnology · 2022Review
- CRISPR-Cas13a system: A novel tool for molecular diagnostics.Frontiers in microbiology · 2022Review
- A highly sensitive and selective fluoride sensor based on a riboswitch-regulated transcription coupled with CRISPR-Cas13a tandem reaction.Chemical science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Recent efforts in biological engineering have made detection of nucleic acids in samples more rapid, inexpensive and sensitive using CRISPR-based approaches. We expand one of these Cas13a-based methods to detect small molecules in a one-batch assay. Using SHERLOCK-based profiling of in vitrotranscription (SPRINT), in vitro transcribed RNA sequence-specifically triggers the RNase activity of Cas13a. This event activates its non-specific RNase activity, which enables cleavage of an RNA oligonucleotide labeled with a quencher/fluorophore pair and thereby de-quenches the fluorophore. This fluorogenic output can be measured to assess transcriptional output. The use of riboswitches or proteins to regulate transcription via specific effector molecules is leveraged as a coupled assay that transforms effector concentration into fluorescence intensity. In this way, we quantified eight different compounds, including cofactors, nucleotides, metabolites of amino acids, tetracycline and monatomic ions in samples. In this manner, hundreds of reactions can be easily quantified in a few hours. This increased throughput also enables detailed characterization of transcriptional regulators, synthetic compounds that inhibit transcription, or other coupled enzymatic reactions. These SPRINT reactions are easily adaptable to portable formats and could therefore be used for the detection of analytes in the field or at point-of-care situations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.